Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asahi Kasei Pharma has received Japanese approval for manufacturing and selling 56.5µg subcutaneous injection formulation of Teribone (generic name: teriparatide acetate, development code: MN-10-T) to treat osteoporosis with high risk of fracture, in Japan.
Subscribe to our email newsletter
The results from a Phase III trial showed with weekly subcutaneous injections for 72 weeks, Teribone helps in decreasing the risk of developing new vertebral fracture by 78.6% compared to placebo treatment.
Teribone is a human parathyroid hormone preparation that facilitates bone formulation.